ipilimumab,nivolumab
bms
['sclc', 'nivolumab', 'check,mate,227', 'lung', 'ipilimumab', 'nivo', 'nsclc']
five-year survival outcomes with nivolumab (nivo) plus ipilimumab (ipi) versus chemotherapy (chemo) as first-line (1l) treatment for metastatic non small cell lung cancer (nsclc): results from checkmate 227. #asco22 
Medicina Interna - Oncología Clínica - Profesor Titular @UPBColombia - Clínica Astorga. #Medellín / #Colombia mlujanonco@gmail.com #OncTwitter #Metaanalysis